InvestorsHub Logo
Followers 37
Posts 7142
Boards Moderated 1
Alias Born 09/06/2014

Re: Gold Seeker post# 25729

Tuesday, 10/21/2014 5:02:45 PM

Tuesday, October 21, 2014 5:02:45 PM

Post# of 30046
The text on that GCDX Order page changed to

"The Lung Cancer Test™ is available."

That TM is a lie - the trademark was abandoned. But more important: the PR said "All required Clinical Validation studies are complete with excellent results." Says who? Who would believe that without seeing the study details and the results? I question whether there even WAS a Validation Study.

Hopefully the FDA will make GCDx publish this "Validation Study" and explain how the results were "excellent."

The only thing we know for certain is: Radient is not involved, and RXPC shareholders will not benefit from anything GCDx does.

The two loudest cheers of the Radient Takeover Theorists were "it's all about the patent" and "Gartner the Leader is a biotech genius." Those cheers have fallen silent now that the patent is dead and Gartner is obviously on his own. So is anyone still cheering? If so, please explain what there is to cheer about.

What's left for Takeover Fantasy? Does it now rely solely on Provista using Radient's DR-70 in their tests? That misconception should be debunked soon when Provista releases their results and there is no mention of fibrin or fibrinogen.

As for CIT... I think Radient said it best when they said in the final 10K that CIT was worth nothing. I trust their judgement on that.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.